Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice

References

• Rowland L, Schneider N. Amyotrophic lateral sclerosis. N Engl J Med. 2001; 344: 1688–700
   PubMed Web of Science ®Google Scholar
• Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993; 362: 59–62
   PubMed Web of Science ®Google Scholar
• Andersen PM, Sims KB, Xin WW, Kiely R, O'Neill G, Ravits J, et al. Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003; 4: 62–73
   PubMed Web of Science ®Google Scholar
• Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994; 264: 1772–5
   PubMed Web of Science ®Google Scholar
• Ryu H, Ferrante RJ. Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Rev Med Chem. 2007; 7: 141–50
   PubMed Web of Science ®Google Scholar
• DiBernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochim Biophys Acta. 2006; 1762: 1139–49
   PubMed Web of Science ®Google Scholar
• Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998; 50: 62–6
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005; 93: 1087–98
   PubMed Web of Science ®Google Scholar
• Wu AS, Kiaei M, Aguirre N, Crow JP, Calingasan NY, Browne SE, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem. 2003; 85: 142–50
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med. 1999; 5: 347–50
   PubMed Web of Science ®Google Scholar
• Olney JW, de Gubareff T. Glutamate neurotoxicity and Huntington's chorea. Nature. 1978; 271: 557–9
   PubMed Web of Science ®Google Scholar
• van den Bosch L, van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006; 1762: 1068–82
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994; 330: 585–91
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996; 347: 1425–31
   PubMed Web of Science ®Google Scholar
• Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996; 47(Suppl 4)S233–41
   PubMed Web of Science ®Google Scholar
• Martin D, Thompson MA, Nadler JV. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur J Pharmacol. 1993; 250: 473–6
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wang KY, Wang WC. Mechanisms underlying riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). Neuroscience. 2004; 125: 191–201
   PubMed Web of Science ®Google Scholar
• Albo F, Pieri M, Zona C. Modulation of AMPA receptors in spinal motor neurons by the neuroprotective agent riluzole. J Neurosci Res. 2004; 78: 200–7
   PubMed Web of Science ®Google Scholar
• Hubert JP, Delumeau JC, Glowinski J, Premont J, Doble A. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action. Br J Pharmacol. 1994; 113: 261–7
   PubMed Web of Science ®Google Scholar
• Fumagalli E, Bigini P, Barbera S, de Paola M, Mennini T. Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motor neuron death in the wobbler mouse, a model of neurodegenerative disease. Exp Neurol. 2006; 198: 114–28
   PubMed Web of Science ®Google Scholar
• Kriz J, Gowing G, Julien JP. Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann Neurol. 2003; 53: 429–36
   PubMed Web of Science ®Google Scholar
• Snow RJ, Turnbull J, da Silva S, Jiang F, Tarnopolsky MA. Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience. 2003; 119: 661–7
   PubMed Web of Science ®Google Scholar
• Waibel S, Reuter A, Malessa S, Blaugrund E, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol. 2004; 251: 1080–4
   PubMed Web of Science ®Google Scholar
• Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005; 112: 649–60
   PubMed Web of Science ®Google Scholar
• Malaspina A, Kaushik N, De Beleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem. 2001; 77: 132–45
   PubMed Web of Science ®Google Scholar
• Ishigaki S, Niwa J, Ando Y, Yoshihara T, Sawada K, Doyu M, et al. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords: screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. 2002; 531: 354–8
   PubMed Web of Science ®Google Scholar
• Gonzalez de Aguilar JL, Gordon JW, Rene F, de Tapia M, Lutz-Bucher B, Gaiddon C, et al. Alteration of Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis. 2000; 7: 406–15
   PubMed Web of Science ®Google Scholar
• Olsen MK, Roberds SL, Ellerbrock BR, Fleck TJ, McKinley DK, Gurney ME. Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann Neurol. 2001; 50: 730–40
   PubMed Web of Science ®Google Scholar
• Cremer JE, Lai JC, Sarna GS. Rapid blood brain transport and metabolism of butyrate and pyruvate in the rat after portocaval anastomosis. J Physiol. 1977; 266: 70–1
   Web of Science ®Google Scholar
• Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial. Blood. 1995; 85: 43–9
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002; 13: 1–13
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Andres PL, Schoenfeld D, Zhang H, Sherman A, Yu H, et al. Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS. Neurology. 2007; 68(Suppl 1)A90
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse of amyotrophic lateral sclerosis. J Mol Neurosci. 2001; 17: 89–96
   PubMed Web of Science ®Google Scholar
• Wang CY, Mayo MW, Baldwin AS., Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappa B. Science. 1996; 274: 784–7
   PubMed Web of Science ®Google Scholar
• Mayo MW, Denlinger CE, Broad RM, Yeung F, Reilly ET, Shi Y, et al. Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kB through the Akt pathway. J Biol Chem. 2003; 278: 18980–9
   PubMed Web of Science ®Google Scholar
• Pennypacker KR, Kassed CA, Eidizadeh S, Saporta S, Sanberg PR, Willing AE. NF-kB p50 is increased in neurons surviving hippocampal injury. Exp Neurol. 2001; 172: 307–19
   PubMed Web of Science ®Google Scholar
• Bruijn LI, Miller TM, Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci. 2004; 27: 723–49
   PubMed Web of Science ®Google Scholar
• Choudry RB, Cudkowicz ME. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future. J Clin Pharmacol. 2005; 45: 1334–44
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Urbinelli L, et al. A clinical trial of creatine in ALS. Neurology. 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001;57:397–404.
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59: 1541–50
   PubMed Web of Science ®Google Scholar
• Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, et al. Tolerance of high-dose (3000 mg/day) coenzyme Q10 in ALS. Neurology. 2005; 65: 1834–6
   PubMed Web of Science ®Google Scholar
• Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol. 1999; 43: 445–53
   PubMed Web of Science ®Google Scholar
• Chang J-G, Hsieh-Li H-M, Jong Y-J, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci. 2001; 98: 9808–13
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003; 23: 9418–27
   PubMed Web of Science ®Google Scholar
• Warrell RPJr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst. 1998; 90: 1621–5
   PubMed Web of Science ®Google Scholar
• Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, et al. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res. 2001; 7: 2292–2300
   PubMed Web of Science ®Google Scholar